Adverse drug reaction of Ramucirumab in patients with gastroesophageal junction cancer

Ramucirumab is the first recombinant human IgG1 monoclonal antibody developed for the treatment of solid cancers and is given as a single drug. Studies have demonstrated that it has survival benefits in patients with advanced gastric or gastro esophageal junction (GEJ) adeno-carcinoma progressing after first-line chemotherapy. Common side effects of Inj. Ramucirumab include Diarrhea, Epistaxis, leucopenia, hypertension or lethargy/malaise. Detailed case reports on adverse drug reactions of Inj. Ramucirumab are lacking, and we hereby present a case report of a patient with GEJ cancer who developed symptoms that mimicked cardiac toxicity immediately after starting Inj. Ramucirumab.